Psoriatic Arthritis Clinical Pipeline | 20+ Companies Driving the Next Wave of Innovation

The Psoriatic Arthritis market is advancing rapidly, driven by groundbreaking research and innovative therapies.

DelveInsight's 'Psoriatic Arthritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Psoriatic Arthritis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Psoriatic Arthritis pipeline domain.

For Psoriatic Arthritis emerging drugs, the Psoriatic Arthritis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Psoriatic Arthritis Pipeline Report
• DelveInsight's Psoriatic Arthritis Pipeline analysis depicts a robust space with 20+ active players working to develop 25+ pipeline drugs for Psoriatic Arthritis treatment.
• The leading Psoriatic Arthritis companies include Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc., and others are evaluating their lead assets to improve the Psoriatic Arthritis treatment landscape.
• Key Psoriatic Arthritis pipeline therapies in various stages of development include Bimekizumab, Tildrakizumab, Deucravacitinib, Izokibep,Sotyktu, HS-10374, si-544, and others.
• In December 2024, Celltrion announced that the FDA approved STEQEYMA (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), for subcutaneous injection or intravenous infusion. It is approved for adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
• In October 2024, Dong-A-ST announced that its Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, received FDA approval for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
• In September 2024, UCB announced that the FDA had approved BIMZELX (bimekizumab-bkzx) for adults with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis. This makes BIMZELX the first and only IL-17A and IL-17F inhibitor approved in the U.S. for these four chronic immune-mediated inflammatory diseases.
• In February 2024, The FDA has accepted UCB's supplemental Biologics License Application (sBLA) for bimekizumab, targeting three new indications, including Psoriatic Arthritis. This development follows the outcomes of four Phase III clinical trials evaluating bimekizumab's effectiveness in PsA, ankylosing spondylitis, and non-radiographic axial spondyloarthritis

Request a sample and discover the recent breakthroughs happening in the Psoriatic Arthritis pipeline landscape @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriatic Arthritis Overview
Psoriatic arthritis (PsA) is a chronic inflammatory joint condition intricately linked to psoriasis, a skin disorder characterized by red, scaly patches and thickened, pitted nails. Affecting approximately 20% of individuals with psoriasis, PsA shares similarities with rheumatoid arthritis (RA), particularly in joint inflammation and swelling. While typically seronegative, some patients may test positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies. The exact cause of PsA remains a puzzle, but genetic predisposition and environmental triggers play significant roles in sparking immune-driven inflammation that targets the skin, joints, and other organs. Studies suggest that up to half of PsA patients have a first-degree relative with psoriasis or PsA. Key genetic contributors include genes in the HLA region, which regulate immune recognition, as well as non-HLA genes that influence immune activation, cytokine expression, and T-cell function.

Diagnosis can be challenging since no single test confirms PsA. Blood markers like ESR and CRP may be elevated but are not always reliable. Imaging studies often reveal unique bone and joint changes, including erosions, joint space narrowing, and the characteristic "pencil-in-cup" deformity. Unlike ankylosing spondylitis, PsA-related spinal changes tend to be asymmetric and discontinuous. Left untreated, PsA can lead to permanent joint damage, highlighting the importance of early intervention.

Treatment focuses on reducing inflammation and preventing joint deterioration. NSAIDs like ibuprofen provide relief for mild cases, while conventional DMARDs such as methotrexate help slow disease progression. For more severe or treatment-resistant cases, biologics and targeted synthetic DMARDs like tofacitinib offer stronger immune regulation. Apremilast provides an oral alternative for those with milder symptoms. By managing inflammation early, individuals with PsA can maintain mobility and improve their overall quality of life.

Find out more about Psoriatic Arthritis medication @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriatic Arthritis Treatment Analysis: Drug Profile
Sotyktu (Deucravacitinib) - Bristol Myers Squibb
Sotyktu (deucravacitinib) is a first-in-class, oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2), offering a novel approach to treating immune-mediated diseases. Unlike traditional JAK inhibitors, Sotyktu targets the regulatory domain of TYK2, achieving allosteric inhibition while maintaining selectivity at therapeutic doses. By blocking TYK2 signaling, it effectively inhibits key cytokines such as IL-23, IL-12, and Type 1 interferons (IFN), which play a critical role in immune-driven inflammation. With its unique mechanism, Sotyktu avoids inhibition of JAK1, JAK2, and JAK3, reducing the potential for off-target effects. Currently in Phase III clinical development, Sotyktu is being evaluated for its efficacy in treating psoriatic arthritis.

HS-10374 - Hansoh BioMedical R&D Company
HS-10374 is an investigational oral TYK2 inhibitor designed to disrupt the signaling pathways that drive inflammatory immune responses. By blocking TYK2 activity, it prevents downstream activation of pro-inflammatory cytokines implicated in autoimmune diseases like psoriatic arthritis. This targeted approach aims to modulate immune activity while minimizing broader immunosuppressive effects. Currently, HS-10374 is progressing through Phase II clinical trials for psoriatic arthritis, with promising potential as an effective and convenient oral therapy.

si-544 - SelectIon
si-544 is an innovative, selective inhibitor of Kv1.3, a key ion channel expressed in disease-associated effector memory T (TEM) cells. TEM cells are central players in chronic autoimmune inflammation, escaping immune regulation and driving persistent immune activation. By selectively blocking Kv1.3, si-544 aims to restore immune balance and reduce inflammation in psoriatic arthritis and other autoimmune disorders such as atopic dermatitis, rheumatoid arthritis, and multiple sclerosis. Currently in Phase I clinical trials, si-544 represents a new frontier in targeted autoimmune therapy.

Key Psoriatic Arthritis Therapies and Companies
• Bimekizumab: UCB Biopharma
• Tildrakizumab: Sun Pharmaceutical Industries Limited
• Deucravacitinib: BMS
• Izokibep: Affibody AB
• Sotyktu: Bristol Myers Squibb
• HS-10374: Hansoh BioMedical R&D Company
• si-544: selection

Learn more about the novel and emerging Psoriatic Arthritis pipeline therapies @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriatic Arthritis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Psoriatic Arthritis Pipeline Report
• Coverage: Global
• Key Psoriatic Arthritis Companies: Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc., and others.
• Key Psoriatic Arthritis Pipeline Therapies: Bimekizumab, Tildrakizumab, Deucravacitinib, Izokibep,Sotyktu, HS-10374, si-544, and others.

Dive deep into rich insights for drugs used for Psoriatic Arthritis treatment; visit @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Psoriatic Arthritis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Psoriatic Arthritis Pipeline Therapeutics
6. Psoriatic Arthritis Pipeline: Late-Stage Products (Phase III)
7. Psoriatic Arthritis Pipeline: Late-Stage Products (Phase III)
8. Psoriatic Arthritis Pipeline: Mid-Stage Products (Phase II)
9. Psoriatic Arthritis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.